H&T Presspart is a leading developer and manufacturer of drug delivery devices and components. With over 50 years of experience, it has built a global reputation for expertise, quality, and innovation in the pharmaceutical industry. With a wide portfolio of components, device solutions and services, H&T Presspart partners to deliver exceptional customer experience and accelerated routes to market of customers’ drug-device programs.
Device Development & Industrialisation Services
Whether you are starting with an early-stage idea or concept or have a qualified prototype our capabilities range from design, development and prototyping to piloting and industrialization of complex respiratory drug delivery devices.
Our team will support you in every step of the process to deliver high quality drug delivery solutions that patients can trust. Our teams are also working hard behind the scenes in developing new technology platforms so we can impact tomorrow together.
Metered-dose Inhaler Cans & Actuators
H&T Presspart is the world’s leading manufacturer of MDI cans and actuators, and so a key partner to the world’s large pharmaceutical companies working in respiratory drug delivery.
We offer a complete range of MDI cans, designing them for optimum compatibility with your chosen valves, actuators and drug formulations. Our standard canisters are 14ml, 17ml, 19ml and we can design and manufacture customised sizes. We also offer soft-mist inhaler sleeves for generic SMI devices.
H&T Presspart offer a range of standard or customised actuator geometries to meet our customers specifications. Our actuators are compatible with all standard pharmaceutical valves and are suitable for all propellants including the next generation low GWP propellants.
Dose Counting Solutions
H&T Presspart offers an FDA approved mechanised dose counting solution, compatible with all marketed MDI valves. Available in 120 dose or 200 dose solutions with flexible pre-count available.
Sustainable Inhalation Devices
With H&T Presspart’s low global warming potential (GWP) propellant laboratory facilities we support development programmes of next generation low GWP metered-dose inhalers with both HFA 152a and HFO1234ze propellants.
H&T Presspart offer small-scale filling capabilities in GMP conditions to support development programs and clinical trials with both HFA-152a and HFO-1234ze propellants. Our Inhalation Product Technology Centre offer a full range of in-vitro testing to support customers with product development, analytical services and product transfers to these novel propellants.
Plasma Surface Treatment Technology
H&T Presspart offers a unique plasma process – manufactured under license from Portal Medical Ltd – for treating the internal surfaces of metered-dose inhaler (MDI) canisters, which ensures the active drug content doesn’t stick to the canister wall. This solves a problem present in many other MDI cans and ensures the patient gets the correct dose.
This fluorocarbon polymerisation (FCP) plasma treatment process improves the surface energy performance of an MDI canister, which enhances drug stability in formulations where interactions with the aluminium substrate can lead to product degradation and reduced shelf life.
Sunriser Dry Powder Inhaler Technology
H&T Presspart has developed a highly efficient technology, Sunriser, that delivers dry powder formulations with fine particle fractions higher than current marketed devices. The technology is suitable for different types of formulations such as classic carrier-based formulations or spray-dried particles alone.
PowdAir Plus Dry Powder Inhaler
Our PowdAir Plus capsule DPI device brings simplicity to patients in delivering any dry powder medicine. Neat and compact with only four components and no metal parts. Affordable inhalation drug delivery designed to make patients‘ lives easier.